Collins: Monoclonal Momentum

12/13/2002 12:00 am EST

Focus:

Jim Collins

Chairman and CEO, Insight Capital Research & Management, Inc.

Jim Collins has spent 40 years in the investment markets, with 25 of them devoted to developing quantitiative techniques. The most important determinant of stock prices, in his view, are earnings. Says the editor of OTC Insight, "It is important to remain disciplined and focus on fundamentals and earnings. Earnings ultimately drive stock prices." Here's a current favorite.

"Immunocor (BLUD NASDAQ) is a global leader that develops and sells a complete line of reagents and automated systems used primarily by hospitals, clinical labs, and blood banks to detect and identify properties of human blood. Its products significantly reduce the amount of time required to perform routine blood tests. The company is also actively engaged in developing monclonal antibodies for the detection of blood group and infectious disease antigens. Monoclonal antibodies are highly specific, a trait which allows them to detect and identify antigens with greater efficiency than other reagents.

"In October, the company updated its guidance for the year. Immunocor expects revenues for the fiscal year ended May 2003 to range from $95 to $96.5 million. Net income is estimated to increase 53% to 60%. The company believes it will generate record earnings of $1.01 to $1.06 for the full fiscal year. The stock is currently trading near its all-time high of $24.20, reached on November 11. The stock receives an A rating for accumulation and distribution and has a relative strength rating of 99. We consider BLUD among the most attractive stocks to buy at the current time."

Related Articles on

Keyword Image
How to Play Preferreds
1 hour ago

Preferred shares are one pocket of the fixed income market where investors can still typically find ...